Trials / Completed
CompletedNCT03809429
Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
A Randomised, Controlled, Open Label, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of Individualised FE 999049 (Follitropin Delta) Dosing, Using a Long GnRH Agonist Protocol and a GnRH Antagonist Protocol in Women Undergoing Controlled Ovarian Stimulation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 437 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FE 999049 + GnRH agonist (GONAPEPTYL) | Pre-filled injection pen |
| DRUG | FE 999049 + GnRH antagonist (CETROTIDE) | Powder and solvent for solution for injection |
Timeline
- Start date
- 2019-04-29
- Primary completion
- 2022-02-16
- Completion
- 2022-02-16
- First posted
- 2019-01-18
- Last updated
- 2024-05-13
- Results posted
- 2024-05-13
Locations
16 sites across 7 countries: Austria, Denmark, Israel, Italy, Netherlands, Norway, Switzerland
Source: ClinicalTrials.gov record NCT03809429. Inclusion in this directory is not an endorsement.